Association of ITPA 94C>A genetic polymorphisms with azathioprine induced adverse effects in the South Indian population

Reka Deva; Priyadharsini Rajendran; Sivaranjini Ramasamy; Senthamizh Selvan; Kesavan Ramasamy

doi:10.1515/dmpt-2023-0061

Article

Association of ITPA 94C>A genetic polymorphisms with azathioprine induced adverse effects in the South Indian population

Reka Deva , Priyadharsini Rajendran , Sivaranjini Ramasamy , Senthamizh Selvan and Kesavan Ramasamy

Published/Copyright: December 15, 2023

Published by

Become an author with De Gruyter Brill

Submit Manuscript Author Information

From the journal Drug Metabolism and Personalized Therapy Volume 39 Issue 1

Abstract

Objectives

Azathioprine (AZA) is an effective immunosuppressant commonly used for malignancy and immune-mediated disorders. The association between genetic polymorphisms and AZA-induced adverse effects has not been elucidated. Hence this study aimed to evaluate the relationship between single nucleotide polymorphisms of ITPA (C94A) with azathioprine-induced adverse effects.

Methods

A cross-sectional study was performed on 120 patients who were on AZA therapy for immunobullous disorders and inflammatory bowel disease (IBD). Eligible patients were enrolled from outpatient Departments of dermatology and medical gastroenterology and five mL of blood was collected after obtaining written informed consent. DNA extraction and genotyping were done by phenol–chloroform method and real-time polymerase chain reaction (RT-PCR), respectively.

Results

The minor allele frequency of ITPA (A allele) was 30.8 %. The mutant genotypes of ITPA (C94A) were found to have no significant association with overall adverse effects in the South Indian patients on AZA therapy.

Conclusions

We report no significant association between ITPA rs1127354 genetic polymorphism and adverse effects in the South Indian patients on AZA therapy.

Keywords: pharmacogenetics; pre-emptive testing; azathioprine therapy

Corresponding author: Reka Deva, Pharmacology, JIPMER, Puducherry 605006, India, E-mail: meetdr.reka478@gmail.com

Acknowledgments

Pharmacogenomics Lab, Department of Pharmacology, JIPMER, Puducherry.

Research ethics: Institute Ethics Committee (IEC) for human observational studies were obtained (JIP/IEC/2019/194). The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).
Informed consent: Written informed consent was obtained from all the participants.
Author contributions: Deva Reka and Rajendran Priyadharsini have contributed to the conception, analysis and interpretation of the study. Ramasamy Sivaranjini and Senthamizh Selvan helped in acquisition of the data. Ramasamy Kesavan helped in revising the important intellectual content. All the authors have accepted responsibility for the entire content of this manuscript and approved its submission.
Competing interests: The authors state no conflict of interest.
Research funding: The study was financially funded by Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER) Intramural Research Grant (JIP/Dean(R)/Intramural/phs1/2019-20).
Data availability: Not applicable.

References

1. Cattaneo, D, Perico, N, Remuzzi, G. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy: from pharmacokinetics to pharmacogenomics. Am J Transplant 2004;4:299–310, https://doi.org/10.1111/j.1600-6143.2004.00312.x.Search in Google Scholar PubMed

2. Sahasranaman, S, Howard, D, Roy, S. Clinical pharmacology and pharmacogenetics of thiopurines. Eur J Clin Pharmacol 2008;64:753–67, https://doi.org/10.1007/s00228-008-0478-6.Search in Google Scholar PubMed

3. Walker, GJ, Harrison, JW, Heap, GA, Voskuil, MD, Andersen, V, Anderson, CA, et al.. Association of genetic variants in NUDT15 with thiopurine-induced myelosuppression in patients with inflammatory bowel disease. JAMA 2019;321:773–85, https://doi.org/10.1001/jama.2019.0709.Search in Google Scholar PubMed PubMed Central

4. Jung, YS, Cheon, JH, Hong, SP, Kim, TI, Kim, WH. Clinical outcomes and prognostic factors for thiopurine maintenance therapy in patients with intestinal Behcetʼs disease. Inflamm Bowel Dis 2012;18:750–7, https://doi.org/10.1002/ibd.21757.Search in Google Scholar PubMed

5. Khera, S, Trehan, A, Bhatia, P, Singh, M, Bansal, D, Varma, N. Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2019;83:341–8, https://doi.org/10.1007/s00280-018-3732-3.Search in Google Scholar PubMed

6. Gisbert, JP, Gomolln, F. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008;103:1783–800, https://doi.org/10.1111/j.1572-0241.2008.01848.x.Search in Google Scholar PubMed

7. Relling, MV, Hancock, ML, Rivera, GK, Sandlund, JT, Ribeiro, RC, Krynetski, EY, et al.. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999;91:2001–8, https://doi.org/10.1093/jnci/91.23.2001.Search in Google Scholar PubMed

8. Relling, MV, Gardner, EE, Sandborn, WJ, Schmiegelow, K, Pui, C-H, Yee, SW, et al.. Clinical pharmacogenetics implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 2013;93:324–5, https://doi.org/10.1038/clpt.2013.4.Search in Google Scholar PubMed PubMed Central

9. Srimartpirom, S, Tassaneeyakul, W, Kukongviriyapan, V, Tassaneeyakul, W. Thiopurine S-methyltransferase genetic polymorphism in the Thai population. Br J Clin Pharmacol 2004;58:66–70, https://doi.org/10.1111/j.1365-2125.2004.02112.x.Search in Google Scholar PubMed PubMed Central

10. Tanaka, Y, Manabe, A, Nakadate, H, Kondoh, K, Nakamura, K, Koh, K, et al.. The activity of the inosine triphosphate pyrophosphatase affects the toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children. Leuk Res 2012;36:560–4, https://doi.org/10.1016/j.leukres.2011.11.015.Search in Google Scholar PubMed

11. Gopisankar, MG. Quality, quantity and recovery of DNA content from routine blood samples and genotyping success rate: comparison between phenol chloroform method (PCM) with a new kit-based DNA extraction method (KBM). Int J Basic Clin Pharmacol 2018;10:1863–8.10.18203/2319-2003.ijbcp20183826Search in Google Scholar

12. Hardy-Weinberg Principle – an overview | ScienceDirect Topics [Internet]. Available from: https://www.sciencedirect.com/topics/neuroscience/hardy-weinberg-principle [accessed 6 Sep 2021].Search in Google Scholar

13. Chen, Z-Y, Zhu, Y-H, Zhou, L-Y, Shi, W-Q, Qin, Z, Wu, B, et al.. Association between genetic polymorphisms of metabolic enzymes and azathioprine-induced myelosuppression in 1,419 Chinese patients: a retrospective study. Front Pharmacol 2021;12:672–9, https://doi.org/10.3389/fphar.2021.672769.Search in Google Scholar PubMed PubMed Central

14. Marinaki, AM, Duley, JA, Arenas, M, Ansari, A, Sumi, S, Lewis, CM, et al.. Mutation in the ITPA gene predicts intolerance to azathioprine. Nucleosides Nucleotides Nucleic Acids. 2004;23:1393–7, https://doi.org/10.1081/ncn-200027639.Search in Google Scholar PubMed

15. Citterio-Quentin, A, Moulsma, M, Gustin, M-P, Lachaux, A, Boulieu, R. ITPA activity in children treated by azathioprine: relationship to the occurrence of adverse drug reactions and inflammatory response. Basic Clin Pharmacol Toxicol 2018;122:588–95.10.1111/bcpt.12958Search in Google Scholar PubMed

16. Dorababu, P, Nagesh, N, Linga, VG, Gundeti, S, Kutala, VK, Reddanna, P, et al.. Epistatic interactions between thiopurine methyltransferase (TPMT) and inosine triphosphate pyrophosphatase (ITPA) variations determine 6-mercaptopurine toxicity in Indian children with acute lymphoblastic leukemia. Eur J Clin Pharmacol 2012;68:379–87, https://doi.org/10.1007/s00228-011-1133-1.Search in Google Scholar PubMed

17. Marinaki, AM, Ansari, A, Duley, JA, Arenas, M, Sumi, S, Lewis, CM, et al.. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004;14:181–7, https://doi.org/10.1097/00008571-200403000-00006.Search in Google Scholar PubMed

18. Choi, R, Lee, M, Kim, K, Baek, S, Kim, TJ, Hong, SN, et al.. Effects of various genetic polymorphisms on thiopurine treatment-associated outcomes for Korean patients with Crohn’s disease. Br J Clin Pharmacol 2020;86:2302–13, https://doi.org/10.1111/bcp.14339.Search in Google Scholar PubMed PubMed Central

Received: 2023-07-24

Accepted: 2023-10-30

Published Online: 2023-12-15

You are currently not able to access this content.

Articles in the same Issue

https://doi.org/10.1515/dmpt-2023-0061

Keywords for this article

pharmacogenetics; pre-emptive testing; azathioprine therapy